DelveInsight’s Non-small Cell Lung Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-small cell lung cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Request for sample report @ Non-small Cell Lung Cancer Market Insights
Key Takeaways from the Non-small Cell Lung Cancer Market Report
- As per DelveInsight’s analysis, the non-small cell lung cancer market is anticipated to grow at a significant CAGR by 2032.
- According to the assessment done by DelveInsight, the United States had 227K incident cases of lung cancer in 2020, of which ~85%, i.e., 193K were NSCLC cancer patients.
- Leading non-small cell lung cancer companies such as EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others are developing novel non-small cell lung cancer drugs that can be available in the non-small cell lung cancer market in the coming years.
- Some of the key therapies for non-small cell lung cancer treatment include M1774, C-TIL051, ACY-241 + Nivolumab, 18F-AraG, Nivolumab + Plinabulin, JIN-A02, FWD1509 MsOH, Osimertinib, BMS-813160, Sutetinib Maleate Capsule, Sotorasib and Tarloxotinib, RH324, AMG 794, Capmatinib, H002, VIC-1911, MYTX-011, ITIL-306, Adagrasib, DS-1062a, NEO-201 in combination with pembrolizumab, PT-112, PBF-1129, REGN2810, RMC-4630, CLN-081, LN-145, IPH5201 + durvalumab + standard chemotherapy, and others.
- On 3rd October 2024, Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab) for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements. This approval covers the use of Opdivo in combination with platinum-doublet chemotherapy as neoadjuvant treatment (before surgery), followed by Opdivo alone as adjuvant therapy (after surgery). The decision is based on results from the CheckMate-77T trial, marking Opdivo as the first PD-1 inhibitor to show significant benefits in both neoadjuvant-only and perioperative regimens for resectable NSCLC.
- On 26 September 2024, AstraZeneca’s Tagrisso (osimertinib) received U.S. approval for treating adult patients with unresectable Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have not experienced disease progression during or after platinum-based chemoradiation therapy. This approval follows the LAURA Phase III trial, which showed that Tagrisso significantly extends median progression-free survival by over three years, specifically for patients with exon 19 deletions or exon 21 (L858R) mutations identified by an FDA-approved test.
- On September 19th, 2024, Johnson & Johnson announced that the FDA has approved RYBREVANT (amivantamab-vmjw) in combination with standard chemotherapy (carboplatin and pemetrexed) for adult patients with locally advanced or metastatic non-small cell lung cancer featuring epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, following disease progression on an EGFR tyrosine kinase inhibitor.
Discover which therapies are expected to grab the major non-small cell lung cancer market share @ Non-small Cell Lung Cancer Market Report
Non-small Cell Lung Cancer Overview
Non-small cell lung cancer (NSCLC) is one of the most prevalent types of lung cancer, accounting for approximately 85% of all lung cancer cases. This malignancy originates in the tissues of the lungs and can spread to other parts of the body if not diagnosed and treated promptly. The primary causes of NSCLC are often related to long-term exposure to harmful substances, particularly cigarette smoking. It is well-established that smokers have a significantly higher risk of developing this form of lung cancer compared to non-smokers.
The symptoms of NSCLC can be subtle in the early stages, making it challenging to detect. Persistent cough, chest pain, shortness of breath, unexplained weight loss, and coughing up blood are some common indicators of the disease. In advanced stages, individuals may experience fatigue, bone pain, and difficulty swallowing, as the cancer spreads to other organs. Diagnosing NSCLC typically involves a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, which help visualize the tumor and its extent. Tissue samples, obtained through procedures like bronchoscopy or biopsy, are examined under a microscope to confirm the presence of cancer cells and determine the specific type and stage of NSCLC.
Non-small Cell Lung Cancer Epidemiology Segmentation
The non-small cell lung cancer epidemiology section provides insights into the historical and current non-small cell lung cancer patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The non-small cell lung cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of NSCLC Patients
- Total Incident Cases of NSCLC Patients by Histology
- Total Diagnosed Cases of NSCLC Patients by Stages
- Total NSCLC Cases of Patients by Genetic Mutation/Biomarkers
- Total Treated Cases of NSCLC Patients by Line of Therapies
Download the report to understand which factors are driving non-small cell lung cancer epidemiology trends @ Non-small Cell Lung Cancer Epidemiological Insights
Non-small Cell Lung Cancer Treatment Market
The treatment of NSCLC involves a multidisciplinary approach tailored to each patient’s specific condition and stage of the disease. Several NSCLC treatment options are available, depending on factors such as tumor size, location, overall health, and the presence of specific genetic mutations. Surgery is often the primary treatment for early-stage NSCLC, aiming to remove the tumor and surrounding tissues. For more advanced cases or when surgery is not feasible, other treatments come into play. These may include radiation therapy, which uses high-energy beams to target and destroy cancer cells, and chemotherapy, where powerful drugs are used to kill cancer cells or slow their growth.
In recent years, targeted therapies and immunotherapy have revolutionized the treatment of NSCLC. Targeted therapies focus on specific genetic mutations present in the cancer cells, disrupting their growth signals and hindering tumor development. On the other hand, immunotherapy harnesses the body’s immune system to recognize and attack cancer cells effectively.
Often, a combination of treatments may be used to achieve the best results, such as combining chemotherapy with immunotherapy or targeted therapy. The choice of NSCLC treatment is a complex decision made by a team of medical professionals, including oncologists, surgeons, and radiation specialists, in consultation with the patient. Research and advancements in NSCLC treatment continue to evolve, providing hope for improved outcomes and better quality of life for individuals battling this challenging disease. Regular follow-up and close monitoring are crucial for evaluating the treatment’s effectiveness and managing any potential side effects.
To know more about non-small cell lung cancer treatment, visit @ Non-small Cell Lung Cancer Treatment Drugs
Key Non-small Cell Lung Cancer Therapies and Companies
- M1774: EMD Serono/Merck
- C-TIL051: Cellular Biomedicine Group, Inc.
- ACY-241 + Nivolumab: Celgene
- 18F-AraG: CellSight Technologies, Inc.
- Nivolumab + Plinabulin: BeyondSpring Pharmaceuticals Inc.
- JIN-A02: J Ints Bio
- FWD1509 MsOH: Forward Pharmaceuticals Co., Ltd.
- Osimertinib: AstraZeneca
- BMS-813160: Bristol-Myers Squibb
- Sutetinib Maleate Capsule: Teligene US
- Sotorasib and Tarloxotinib: Rain Oncology Inc
- RH324: ReHeva Biosciences, Inc.
- AMG 794: Amgen
- Capmatinib: Novartis
- H002: RedCloud Bio/Parexel
- VIC-1911: Vitrac Therapeutics, LLC
- MYTX-011: Mythic Therapeutics
- ITIL-306: Instil Bio
- Adagrasib: Mirati Therapeutics Inc.
- DS-1062a: Daiichi Sankyo, Inc./AstraZeneca
- NEO-201 in combination with pembrolizumab: Precision Biologics, Inc
- PT-112: Promontory Therapeutics Inc.
- PBF-1129: Palobiofarma SL
- REGN2810: Regeneron Pharmaceuticals
- RMC-4630: Revolution Medicines, Inc.
- CLN-081: Cullinan Oncology, LLC
- LN-145: Iovance Biotherapeutics, Inc.
- IPH5201 + durvalumab + standard chemotherapy: Innate Pharma
Learn more about the FDA-approved drugs for non-small cell lung cancer @ Drugs for Non-small Cell Lung Cancer Treatment
Non-small Cell Lung Cancer Market Dynamics
Non-small cell lung cancer market dynamics have undergone significant changes in recent years. As one of the most prevalent types of lung cancer, the NSCLC market has been driven by several key factors. Technological advancements in diagnostic tools, such as next-generation sequencing and liquid biopsies, have improved early detection rates, leading to better patient outcomes. Additionally, the emergence of targeted therapies and immunotherapies has revolutionized treatment options, offering more personalized and effective approaches.
The competitive landscape has also witnessed intense activity, with pharmaceutical companies continuously developing and launching innovative drugs. As a result, the NSCLC market has become highly competitive, prompting pricing pressures and cost-containment efforts from payers and healthcare systems. Alongside this, regulatory changes and evolving reimbursement policies have shaped the access and affordability of NSCLC treatments.
Moreover, patient advocacy groups and increased awareness campaigns have played a pivotal role in driving research funding and shaping healthcare policies, further impacting the NSCLC market. Collaboration between industry stakeholders, academia, and government bodies has accelerated the pace of research and development in this area.
In the dynamic landscape of the NSCLC market, several barriers have emerged, hindering the smooth progression of research, development, and access to effective treatments. Advanced therapies, such as targeted therapies and immunotherapies, often come with a high price tag. The cost of these treatments can pose a significant financial burden on patients and healthcare systems, leading to limited access, especially in regions with constrained healthcare budgets.
Moreover, the process of gaining regulatory approvals for new drugs is lengthy and complex. Stringent requirements and clinical trial standards often lead to delays and substantial financial investments for pharmaceutical companies. This can slow down the introduction of innovative therapies into the NSCLC market.
Scope of the Non-small Cell Lung Cancer Market Report
- Study Period: 2019–2032
- Non-small Cell Lung Cancer Report Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
- Key Non-small Cell Lung Cancer Companies: EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others
- Key Non-small Cell Lung Cancer Therapies: M1774, C-TIL051, ACY-241 + Nivolumab, 18F-AraG, Nivolumab + Plinabulin, JIN-A02, FWD1509 MsOH, Osimertinib, BMS-813160, Sutetinib Maleate Capsule, Sotorasib and Tarloxotinib, RH324, AMG 794, Capmatinib, H002, VIC-1911, MYTX-011, ITIL-306, Adagrasib, DS-1062a, NEO-201 in combination with pembrolizumab, PT-112, PBF-1129, REGN2810, RMC-4630, CLN-081, LN-145, IPH5201 + durvalumab + standard chemotherapy, and others
- Therapeutic Assessment: Non-small Cell Lung Cancer current marketed and emerging therapies
- Non-small Cell Lung Cancer Market Dynamics: Attribute Analysis of Emerging Non-small Cell Lung Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Non-small Cell Lung Cancer Market Access and Reimbursement
Table of Contents
1. Non-small Cell Lung Cancer Market Key Insights
2. Non-small Cell Lung Cancer Market Report Introduction
3. Non-small Cell Lung Cancer Market Overview at a Glance
4. Non-small Cell Lung Cancer Market Executive Summary
5. Disease Background and Overview
6. Non-small Cell Lung Cancer Treatment and Management
7. Non-small Cell Lung Cancer Epidemiology and Patient Population
8. Patient Journey
9. Non-small Cell Lung Cancer Marketed Drugs
10. Non-small Cell Lung Cancer Emerging Drugs
11. Seven Major Non-small Cell Lung Cancer Market Analysis
12. Non-small Cell Lung Cancer Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services